Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development ConSynance Therapeutics Inc Jyant Technologies Inc NeuroNano Pharma Inc Neurotez Inc Novelion Therapeutics Inc XL-protein GmbH Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles Allo-Aca - Drug Profile Product Description Mechanism Of Action R&D Progress CV-08 - Drug Profile Product Description Mechanism Of Action R&D Progress Fusion Protein to Agonize Leptin Receptor for Metabolic Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress memtin - Drug Profile Product Description Mechanism Of Action R&D Progress metreleptin - Drug Profile Product Description Mechanism Of Action R&D Progress Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptide to Agonize Leptin Receptor for Metabolic Disorders and Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress XL-100 - Drug Profile Product Description Mechanism Of Action R&D Progress Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones Featured News & Press Releases Sep 15, 2017: Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society Feb 06, 2017: ConSynance Provides Update on small leptin mimetics for the treatment Alzheimer's Disease Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency Dec 22, 2016: Novelion T

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by ConSynance Therapeutics Inc, H1 2018 Pipeline by Jyant Technologies Inc, H1 2018 Pipeline by NeuroNano Pharma Inc, H1 2018 Pipeline by Neurotez Inc, H1 2018 Pipeline by Novelion Therapeutics Inc, H1 2018 Pipeline by XL-protein GmbH, H1 2018 Dormant Projects, H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

ConSynance Therapeutics Inc Jyant Technologies Inc NeuroNano Pharma Inc Neurotez Inc Novelion Therapeutics Inc XL-protein GmbH